Skip to main content
Erschienen in: Current Colorectal Cancer Reports 4/2017

23.06.2017 | Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?

verfasst von: Michele M. Gage, Matthew T. Hueman

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Up to 50% of patients with stage II or III colon cancer are estimated to develop locoregional recurrence, distant metastasis, or metachronous colon cancers within 5 years of initial treatment. Given the high risk of recurrence, surveillance is critical, but what is the optimal frequency and testing of surveillance, and is it possible to tailor surveillance plans based on risk prediction tools?

Recent Findings

We reviewed the current national guidelines from 6 reputable oncologic organizations, as well as 10 randomized controlled trials and numerous meta-analyses in the last 22 years evaluating more intensive to less intensive surveillance to answer this question. Currently available adjunct testing, such as genomic testing, and risk calculators were also evaluated.

Summary

Overall, high-frequency surveillance, to a limit, has been established as superior to less frequency surveillance. Future research will likely demonstrate evidence for adjunct testing for personalized surveillance screening based on individual recurrence risk.
Literatur
2.
Zurück zum Zitat Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994 Jan;81(1):7–19. Review Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994 Jan;81(1):7–19. Review
3.
Zurück zum Zitat Devesa JM, Morales V, Enriquez JM, Nuño J, Camuñas J, Hernandez MJ, et al. Colorectal cancer. The bases for a comprehensive follow-up. Dis Colon Rectum. 1988 Aug;31(8):636–52. Review Devesa JM, Morales V, Enriquez JM, Nuño J, Camuñas J, Hernandez MJ, et al. Colorectal cancer. The bases for a comprehensive follow-up. Dis Colon Rectum. 1988 Aug;31(8):636–52. Review
4.
Zurück zum Zitat Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997 Jan;40(1):15–24.CrossRefPubMed Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997 Jan;40(1):15–24.CrossRefPubMed
6.
Zurück zum Zitat Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. 3rd; American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10;31(35):4465–70. doi:10.1200/JCO.2013.50.7442.CrossRefPubMed Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. 3rd; American Society of Clinical Oncology. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10;31(35):4465–70. doi:10.​1200/​JCO.​2013.​50.​7442.CrossRefPubMed
8.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v70-7. doi: 10.1093/annonc/mdq168. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v70-7. doi: 10.​1093/​annonc/​mdq168.
9.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72. doi: 10.1093/annonc/mdt354. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D, ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72. doi: 10.​1093/​annonc/​mdt354.
10.
Zurück zum Zitat El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015 Nov-Dec;65(6):428–55. doi:10.3322/caac.21286. Epub 2015 Sep 8 El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015 Nov-Dec;65(6):428–55. doi:10.​3322/​caac.​21286. Epub 2015 Sep 8
12.
Zurück zum Zitat Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015 Aug;58(8):713–25. doi:10.1097/DCR.0000000000000410. Review Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2015 Aug;58(8):713–25. doi:10.​1097/​DCR.​0000000000000410​. Review
13.
Zurück zum Zitat Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. BMC Cancer. 2003 Oct 6;3:26. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, Zuraw L, Zwaal C. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. BMC Cancer. 2003 Oct 6;3:26.
14.
Zurück zum Zitat Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002 Apr 6;324(7341):813. Review Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002 Apr 6;324(7341):813. Review
15.
Zurück zum Zitat Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon rectum. 2007 Nov;50(11):1783–99. Review Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon rectum. 2007 Nov;50(11):1783–99. Review
16.
Zurück zum Zitat Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016 Nov 24;11:CD002200. Review Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016 Nov 24;11:CD002200. Review
17.
Zurück zum Zitat Mäkelä JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg. 1995 Oct;130(10):1062–7.CrossRefPubMed Mäkelä JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg. 1995 Oct;130(10):1062–7.CrossRefPubMed
18.
Zurück zum Zitat Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995 Jun;38(6):619–26.CrossRefPubMed Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum. 1995 Jun;38(6):619–26.CrossRefPubMed
19.
Zurück zum Zitat Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997 May;84(5):666–9.CrossRefPubMed Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997 May;84(5):666–9.CrossRefPubMed
20.
Zurück zum Zitat Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon rectum. 1998 Sep;41(9):1127–33. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon rectum. 1998 Sep;41(9):1127–33.
21.
Zurück zum Zitat Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998 Jan;114(1):7–14.CrossRefPubMed Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology. 1998 Jan;114(1):7–14.CrossRefPubMed
22.
Zurück zum Zitat Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002 Jun;28(4):418–23.CrossRefPubMed Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002 Jun;28(4):418–23.CrossRefPubMed
23.
Zurück zum Zitat Rodríguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006 Jan 20;24(3):386–93.CrossRefPubMed Rodríguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006 Jan 20;24(3):386–93.CrossRefPubMed
24.
Zurück zum Zitat Wang T, Cui Y, Huang WS, Deng YH, Gong W, Li CJ, et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):609–15. doi:10.1016/j.gie.2008.05.017.CrossRefPubMed Wang T, Cui Y, Huang WS, Deng YH, Gong W, Li CJ, et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):609–15. doi:10.​1016/​j.​gie.​2008.​05.​017.CrossRefPubMed
25.
Zurück zum Zitat • Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014 Jan 15;311(3):263-70. doi: 10.1001/jama.2013.285718. Randomized controlled trial comparing survival benefit of intensive screening with CEA, CT, CEA and CT, and minimal follow-up; demonstrated increased rate of surgical treatment for recurrence, however did not show statistically significant survival advantage. • Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D; FACS Trial Investigators. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014 Jan 15;311(3):263-70. doi: 10.​1001/​jama.​2013.​285718. Randomized controlled trial comparing survival benefit of intensive screening with CEA, CT, CEA and CT, and minimal follow-up; demonstrated increased rate of surgical treatment for recurrence, however did not show statistically significant survival advantage.
26.
Zurück zum Zitat • Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, Daniele B, Gaion F, Oliverio G, Duro M, Martignoni G, Pinna N, Sozzi P, Pancera G, Solina G, Pavia G, Pignata S, Johnson F, Labianca R, Apolone G, Zaniboni A, Monteforte M, Negri E, Torri V, Mosconi P, Fossati R; GILDA working group. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016 Feb;27(2):274–80. doi: 10.1093/annonc/mdv541. Randomized trial comparing increased frequency of colonoscopy and imaging after colorectal cancer treatment; follow-up frequency was the same. Demonstrated higher surgical treatment with curative intent, but no significant survival advantage. • Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, Daniele B, Gaion F, Oliverio G, Duro M, Martignoni G, Pinna N, Sozzi P, Pancera G, Solina G, Pavia G, Pignata S, Johnson F, Labianca R, Apolone G, Zaniboni A, Monteforte M, Negri E, Torri V, Mosconi P, Fossati R; GILDA working group. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016 Feb;27(2):274–80. doi: 10.​1093/​annonc/​mdv541. Randomized trial comparing increased frequency of colonoscopy and imaging after colorectal cancer treatment; follow-up frequency was the same. Demonstrated higher surgical treatment with curative intent, but no significant survival advantage.
27.
Zurück zum Zitat Grossmann EM, Johnson FE, Virgo KS, Longo WE, Fossati R. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surg Oncol. 2004 Aug-Nov;13(2–3):119–24.CrossRefPubMed Grossmann EM, Johnson FE, Virgo KS, Longo WE, Fossati R. Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. Surg Oncol. 2004 Aug-Nov;13(2–3):119–24.CrossRefPubMed
28.
Zurück zum Zitat Augestad KM, Norum J, Dehof S, Aspevik R, Ringberg U, Nestvold T, Vonen B, Skrøvseth SO, Lindsetmo RO. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013 Apr 4;3(4). pii: e002391. doi: 10.1136/bmjopen-2012-002391. Print 2013. Augestad KM, Norum J, Dehof S, Aspevik R, Ringberg U, Nestvold T, Vonen B, Skrøvseth SO, Lindsetmo RO. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013 Apr 4;3(4). pii: e002391. doi: 10.​1136/​bmjopen-2012-002391. Print 2013.
30.
Zurück zum Zitat Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, Platell C, Silagy C. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer. 2006 Apr 24;94(8):1116-21. Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, Platell C, Silagy C. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer. 2006 Apr 24;94(8):1116-21.
32.
Zurück zum Zitat Hansdotter Andersson P, Wille-Jørgensen P, Horváth-Puhó E, Petersen SH, Martling A, Sørensen HT, et al. The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clin Epidemiol. 2016 Jan 28;8:15–21. doi:10.2147/CLEP.S92661. eCollection 2016 Hansdotter Andersson P, Wille-Jørgensen P, Horváth-Puhó E, Petersen SH, Martling A, Sørensen HT, et al. The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clin Epidemiol. 2016 Jan 28;8:15–21. doi:10.​2147/​CLEP.​S92661. eCollection 2016
33.
Zurück zum Zitat Mokhles S, Macbeth F, Farewell V, Fiorentino F, Williams NR, Younes RN, et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg. 2016 Sep;103(10):1259–68. doi:10.1002/bjs.10233. Epub 2016 Aug 4 Mokhles S, Macbeth F, Farewell V, Fiorentino F, Williams NR, Younes RN, et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg. 2016 Sep;103(10):1259–68. doi:10.​1002/​bjs.​10233. Epub 2016 Aug 4
34.
Zurück zum Zitat •• Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015 Apr;26(4):644–56. doi: 10.1093/annonc/mdu543. Epub 2014 Nov 19. Systematic review and meta-analysis demonstrating improved outcomes in colorectal cancer patients with intensive follow-up strategies. •• Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015 Apr;26(4):644–56. doi: 10.​1093/​annonc/​mdu543. Epub 2014 Nov 19. Systematic review and meta-analysis demonstrating improved outcomes in colorectal cancer patients with intensive follow-up strategies.
35.
Zurück zum Zitat •• Van der Stok EP, Spaander MC, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2016 Dec 20. Ddoi: 10.1038/nrclinonc.2016.199. Review article with pooled analysis which demonstrated overall survival benefit of intensive surveillance after colorectal cancer treatment. •• Van der Stok EP, Spaander MC, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2016 Dec 20. Ddoi: 10.1038/nrclinonc.2016.199. Review article with pooled analysis which demonstrated overall survival benefit of intensive surveillance after colorectal cancer treatment.
36.
Zurück zum Zitat Guyot F, Faivre J, Manfredi S, Meny B, Bonithon-Kopp C, Bouvier AM. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005 May;16(5):756–61. Epub 2005 Mar 24 Guyot F, Faivre J, Manfredi S, Meny B, Bonithon-Kopp C, Bouvier AM. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005 May;16(5):756–61. Epub 2005 Mar 24
37.
Zurück zum Zitat Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998 Jul 1;129(1):27–35.CrossRefPubMed Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998 Jul 1;129(1):27–35.CrossRefPubMed
38.
Zurück zum Zitat Staab HJ, Anderer FA, Stumpf E, Fischer R. Carcinoembryonic antigen follow-up and selection of patients for second-look operation in management of gastrointestinal carcinoma. J Surg Oncol. 1978;10(3):273–82.CrossRefPubMed Staab HJ, Anderer FA, Stumpf E, Fischer R. Carcinoembryonic antigen follow-up and selection of patients for second-look operation in management of gastrointestinal carcinoma. J Surg Oncol. 1978;10(3):273–82.CrossRefPubMed
39.
Zurück zum Zitat Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ. 2004 Jan 10;328(7431):81.CrossRefPubMedPubMedCentral Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ. 2004 Jan 10;328(7431):81.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980 Apr;23(3):141–4.CrossRefPubMed Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum. 1980 Apr;23(3):141–4.CrossRefPubMed
41.
Zurück zum Zitat Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989 Aug;210(2):127–38. Review Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989 Aug;210(2):127–38. Review
42.
Zurück zum Zitat Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010 Jan;31(1):19–31. doi:10.1002/jmri.22010. Review Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010 Jan;31(1):19–31. doi:10.​1002/​jmri.​22010. Review
43.
Zurück zum Zitat Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al., American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005 Nov 20;23(33):8512–9. Epub 2005 Oct 31 Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al., American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005 Nov 20;23(33):8512–9. Epub 2005 Oct 31
44.
Zurück zum Zitat Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. Pfister DG, Benson AB 3rd, Somerfield MR. N Engl J Med. 2004 Jun 3;350(23):2375-82. Review. No abstract available. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. Pfister DG, Benson AB 3rd, Somerfield MR. N Engl J Med. 2004 Jun 3;350(23):2375-82. Review. No abstract available.
46.
Zurück zum Zitat Seo SI, Lim SB, Yoon YS, Kim CW, Yu CS, Kim TW, et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013 Jul;108(1):9–13. doi:10.1002/jso.23349. Epub 2013 Jun 10 Seo SI, Lim SB, Yoon YS, Kim CW, Yu CS, Kim TW, et al. Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients. J Surg Oncol. 2013 Jul;108(1):9–13. doi:10.​1002/​jso.​23349. Epub 2013 Jun 10
47.
Zurück zum Zitat Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015 Jul;47(7):529–31. doi:10.1016/j.dld.2015.03.021. Epub 2015 Apr 2 Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, et al. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: the FFCD PRODIGE 13 randomised phase III trial. Dig Liver Dis. 2015 Jul;47(7):529–31. doi:10.​1016/​j.​dld.​2015.​03.​021. Epub 2015 Apr 2
48.
Zurück zum Zitat Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK; United States Multi-Society Task Force on Colorectal Cancer. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar;150(3):758-768.e11. doi: 10.1053/j.gastro.2016.01.001. Review. Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Robertson DJ, Rex DK; United States Multi-Society Task Force on Colorectal Cancer. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar;150(3):758-768.e11. doi: 10.​1053/​j.​gastro.​2016.​01.​001. Review.
49.
Zurück zum Zitat Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of intergroup 0089. Ann Intern Med. 2002 Feb 19;136(4):261–9.CrossRefPubMed Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of intergroup 0089. Ann Intern Med. 2002 Feb 19;136(4):261–9.CrossRefPubMed
50.
Zurück zum Zitat Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW. Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2078-84.e1-2. doi: 10.1016/j.cgh.2014.04.017. Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW. Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2078-84.e1-2. doi: 10.​1016/​j.​cgh.​2014.​04.​017.
51.
Zurück zum Zitat Das A, Chak A, Cooper GS. Temporal trend in relative risk of second primary colorectal cancer. Am J Gastroenterol. 2006 Jun;101(6):1342–7.CrossRefPubMed Das A, Chak A, Cooper GS. Temporal trend in relative risk of second primary colorectal cancer. Am J Gastroenterol. 2006 Jun;101(6):1342–7.CrossRefPubMed
52.
Zurück zum Zitat Augestad KM, Rose J, Crawshaw B, Cooper G, Delaney C. Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World J Gastrointest Oncol. 2014 May 15;6(5):104–11. doi:10.4251/wjgo.v6.i5.104. Review Augestad KM, Rose J, Crawshaw B, Cooper G, Delaney C. Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review. World J Gastrointest Oncol. 2014 May 15;6(5):104–11. doi:10.​4251/​wjgo.​v6.​i5.​104. Review
53.
Zurück zum Zitat Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15;22(10):1797–806. Epub 2004 Apr 5 Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004 May 15;22(10):1797–806. Epub 2004 Apr 5
54.
Zurück zum Zitat Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.1093/jnci/dju333. Print 2014 Dec. Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.​1093/​jnci/​dju333. Print 2014 Dec.
55.
Zurück zum Zitat Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011 Dec 10;29(35):4611–9. doi:10.1200/JCO.2010.32.8732. Epub 2011 Nov 7 Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011 Dec 10;29(35):4611–9. doi:10.​1200/​JCO.​2010.​32.​8732. Epub 2011 Nov 7
58.
Zurück zum Zitat Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011 Jan 1;29(1):17–24. doi:10.1200/JCO.2010.30.1077. Epub 2010 Nov 22 Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011 Jan 1;29(1):17–24. doi:10.​1200/​JCO.​2010.​30.​1077. Epub 2010 Nov 22
59.
Zurück zum Zitat Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015 Feb;20(2):127–33. doi:10.1634/theoncologist.2014-0325. Epub 2015 Jan 5 Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. 2015 Feb;20(2):127–33. doi:10.​1634/​theoncologist.​2014-0325. Epub 2015 Jan 5
61.
Zurück zum Zitat Lin HH, Wei NC, Chou TY, Lin CC, Lan YT, Chang SC, Wang HS, Yang SH, Chen WS, Lin TC, Lin JK, Jiang JK. Building personalized treatment plans for early-stage colorectal cancer patients. Oncotarget. 2017 Jan 13. doi: 10.18632/oncotarget.14638. [Epub ahead of print]. Lin HH, Wei NC, Chou TY, Lin CC, Lan YT, Chang SC, Wang HS, Yang SH, Chen WS, Lin TC, Lin JK, Jiang JK. Building personalized treatment plans for early-stage colorectal cancer patients. Oncotarget. 2017 Jan 13. doi: 10.​18632/​oncotarget.​14638. [Epub ahead of print].
Metadaten
Titel
Colorectal Cancer Surveillance: What Is the Optimal Frequency of Follow-up and Which Tools Best Predict Recurrence?
verfasst von
Michele M. Gage
Matthew T. Hueman
Publikationsdatum
23.06.2017
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 4/2017
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0382-5

Weitere Artikel der Ausgabe 4/2017

Current Colorectal Cancer Reports 4/2017 Zur Ausgabe

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Quality Colorectal Cancer Screening: Endoscopic Performance Measures and Beyond

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Clinical Target Volume Definition in Preoperative Radiotherapy of Rectal Carcinoma: a Systematic Review

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Inflammation and Colorectal Cancer

Genetic Syndromes, Screening, and Surveillance in Colorectal Cancer (N Kubiliun, Section Editor)

Adenomatous Polyposis Syndromes: Familial Adenomatous Polyposis and MutYH-Associated Polyposis

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.